A PROSPECTIVE STUDY ON RELATION OF HISTOLOGICAL GRADE AS WELLAS HORMONE RECEPTOR PROFILE IN LOCALLY ADVANCED BREAST CARCINOMA PATIENTS IN RESPONSE TO NEOADJUVANT CHEMOTHERAPY

2021 ◽  
pp. 59-61
Author(s):  
Samir Ranjan ◽  
Arun Gupta
Keyword(s):  
Breast Carcinoma ◽  
Neoadjuvant Chemotherapy ◽  
Prospective Study ◽  
Ductal Carcinoma ◽  
Histological Grade ◽  
Lobular Carcinoma ◽  
Locally Advanced ◽  
Receptor Status ◽  
Her 2 ◽  
A Prospective Study

Introduction: Inltrating ductal carcinoma being the most common type of carcinoma (70%), lobular carcinoma is the 2nd most common followed by smaller groups such as medullary, mucinous,comedo, paget's disease, papillary, tubular and inammatory carcinoma. Aims and objectives:To establish incidence and correlation between ER, PR, HER 2 neu receptor status, histology with different patient proles. Assessment of therapeutic effectivity and its relation with receptor status and histology after neoadjuvant chemotherapy. Material and methods: This will be an institution-based observational and prospective study. Lab studies- hemoglobin, total count, fasting and postprandial blood sugar, urea, creatinine, albumin and total protein Pretested and predesigned perform Conclusion: This study shows that age group is an important factor for developing breast carcinoma, which was more prevalent in premenstrual population.

scholarly journals Assessment of Pathological Response of Breast Carcinoma in Modified Radical Mastectomy Specimens after Neoadjuvant Chemotherapy

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Dhanya Vasudevan ◽  
P. S. Jayalakshmy ◽  
Suresh Kumar ◽  
Siji Mathew
Keyword(s):  
Breast Carcinoma ◽  
Neoadjuvant Chemotherapy ◽  
Lymph Nodes ◽  
Tumor Response ◽  
Ductal Carcinoma ◽  
Locally Advanced ◽  
Radical Mastectomy ◽  
Tumor Characteristics ◽  
Modified Radical Mastectomy ◽  
Tumor Bed

Aim. Paclitaxel based neoadjuvant chemotherapy regimen (NAT) in the setting of locally advanced breast cancer (LABC) can render inoperable tumor (T4, N2/N3) resectable. The aim of this study was to assess the status of carcinoma in the breast and lymph nodes after paclitaxel based NAT in order to find out the patient and the tumor characteristics that correspond to the pathological responses which could be used as a surrogate biomarker to assess the treatment response.Materials and Methods. Clinical and tumor characteristics of patients with breast carcinoma (n=48) were assessed preoperatively. These patients were subjected to modified radical mastectomy after 3 courses of paclitaxel based NAT regimen. The pathological responses of the tumor in the breast and the lymph nodes were studied by using Chevallier’s system which graded the responses into pathological complete response (pCR), pathological partial response (pPR), and pathological no response (pNR).Results. Our studies showed a pCR of 27.1% and a pPR of 70.9% . Clinically small sized tumors (2–5 cms) and Bloom Richardson’s grade 1 tumors showed a pCR. Mean age at presentation was 50.58 yrs. 79.2% of cases were invasive ductal carcinoma NOS; only 2.1% were invasive lobular carcinoma, their response to NAT being the same. There was no downgrading of the tumor grades after NAT. Ductal carcinoma in situ and lymphovascular invasion were found to be resistant to chemotherapy. The histopathological changes noted in the lymph nodes were similar to that found in the tumor bed.Discussion and Conclusion. From our study we conclude that histopathological examination of the tumor bed is the gold standard for assessing the chemotherapeutic tumor response. As previous studies have shown pCR can be used as a surrogate biomarker to assess the tumor response.

scholarly journals Immunohistochemical Expression of Tissue Inhibitor of Metalloproteinase-1 (Timp-1) in Invasive Breast Carcinoma

2009 ◽  
Vol 9 (2) ◽  
pp. 125-130 ◽  
Author(s):  
Suada Kuskunović ◽  
Svjetlana Radović ◽  
Mirsad Dorić ◽  
Ajna Hukić ◽  
Mirsad Babić ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Protein Expression ◽  
Ductal Carcinoma ◽  
Lobular Carcinoma ◽  
Carcinoma Cells ◽  
Tissue Inhibitor Of Metalloproteinase ◽  
Nuclear Staining ◽  
Immunohistochemical Expression ◽  
Tissue Inhibitor ◽  
Her 2

Tissue inhibitor of metalloproteinase-1 (TIMP-1) is a natural inhibitor of matrix metalloproteinas-es (MMPs). Aim of this study was to assess the immunohistochemical expression of TIMP-1 in invasive breast carcinomas, and to examine its association with classical clinico-pathological parameters, oestrogen receptor, progesterone receptor and Her-2/neu protein expression. Immuno-histochemistry was used to determine the expression of TIMP-1 on 38 paraffin-embedded breast tissue specimens - 18 with invasive ductal carcinoma, 10 with invasive lobular carcinoma, and 10 specimens from patients with fibrocystic breast disease. TIMP-1 protein was immunodetected in the carcinoma cells, fibroblasts and inflammatory cells of the stroma in 92,9%, 65,8%, and 65,8% of cases, respectively. TIMP-1 protein expression in carcinoma cells showed positive correlation with TIMP-1 protein expression in peritumoural fibroblasts (p=0,010). Positive peritumoural fibroblast TIMP-1 expression was associated with histological tumour type with higher frequency in ductal carcinomas (p=0,023). Negative association was found between TIMP-1 protein expression in carcinoma cells and HER-2/neu nuclear staining (p=0,005). TIMP-1 may be particularly useful as a predictive marker in breast carcinoma when evaluated along with HER-2/neu protein being a promising indicator of favourable prognosis in breast carcinoma.

scholarly journals Role of neoadjuvant chemotherapy in downstaging locally advanced breast carcinoma, selection of surgical procedure and its outcome

2020 ◽  
Vol 7 (2) ◽  
pp. 526
Author(s):  
Dakshayani S. Nirhale ◽  
Rizhin Sooraj ◽  
Anshu Rawat
Keyword(s):  
Breast Carcinoma ◽  
Neoadjuvant Chemotherapy ◽  
Ductal Carcinoma ◽  
Locally Advanced Breast Cancer ◽  
Clinical Stage ◽  
Locally Advanced ◽  
Radical Mastectomy ◽  
Conservative Surgery ◽  
Advanced Breast ◽  
Number Of Patients

Background: In clinical practice all cases of locally advanced breast carcinoma (LABC) warrant chemotherapy followed by multimodality care. Neoadjuvant chemotherapy (NACT) has been the mainstay in the management of LABC. The main aim of NACT is to downstage and prevent systemic micrometastasis early.Methods: This was a prospective study conducted on 36 diagnosed cases of stage III locally advanced breast cancer coming to the Dept. of Surgery, Dr. D. Y. Patil Medical College and hospital, Pune for a period of 2 years from 2017-2019. The effectiveness of neoadjuvant chemotherapy was assessed based on clinical, pathological and radiological response.Results: Among 36 LABC cases, maximum number of patients fell in the 41-50 years (41.6%) and presented in the Infiltrating ductal carcinoma group with a clinical stage IIIA disease. The response to NACT showed that a total of 12 patients (33.3%) showed complete clinical response and 30 patients were downstaged after neoadjuvant chemotherapy which was statistically significant. Only 4 out of the total 12 complete clinical responders went for Breast conservative surgery. Seroma formation was found to be the most common post-operative complication.Conclusions: LABC subjected to neoadjuvant chemotherapy based on taxanes/Anthracyclines show good clinical and radiological response. Patients preferred modified radical mastectomy due to the lack of awareness and low socioeconomic strata.The type of surgery did not increase  the chance of recurrence in the follow up period. 

scholarly journals Expression of anaplastic lymphokinase and HER2/neu immunostaining in patients with breast carcinoma

2018 ◽  
Vol 6 (11) ◽  
pp. 3472
Author(s):  
Syed Naqeeb Ali ◽  
Aneela Qureshi ◽  
Amin Fahim ◽  
Muhammad Yousif Khoso
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Breast Carcinoma ◽  
Ductal Carcinoma ◽  
Histological Grade ◽  
Lobular Carcinoma ◽  
Breast Cancer Patients ◽  
Ki 67 ◽  
Cross Sectional ◽  
Tissue Samples

Background: The diagnosis and prognosis of breast cancer is done with various immunomarkers including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2/neu), and Ki-67. The diagnostic utility of Anaplastic Lymphokinase (ALK) and HER2/neu should be explored for better management of breast carcinoma patients. So, the present study was designed to determine the expression of immunostaining with ALK and HER2/neu in patients with breast cancer and to compare the association of ALK expression and HER2/neu with clinicopathological parameters.Methods: This is a cross sectional multicenter study carried out from October 2016 to March 2017. A total of 140 subjects having breast carcinoma by using non-probability purposive sampling technique were selected. After taking informed consent, tissue samples were taken from received specimen of mastectomy for hematoxylin and eosin stain. The immunohistochemistry for ALK and HER2/neu were assessed on the paraffin blocks of the tumor.Results: Out of total 140 cases invasive ductal carcinoma (89%), invasive lobular carcinoma (8%), invasive medullary carcinoma (2.1%) and papillary carcinoma (0.7%) were seen. ALK expression was positive in 81 patients (58%) while HER2/neu expression was positive in 53 cases (38%). Significant association was observed between ALK expression with histological grade, lymph node involvement, skin involvement and necrosis. There was also a significant association was seen between HER2/neu expression with lymph node metastasis and necrosis.Conclusions: Present study shows higher expression of ALK when compared to HER2/neu expression in breast cancer patients.

Sign in / Sign up

Export Citation Format

Share Document